Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mirum Pharmaceuticals, Inc.

https://mirumpharma.com

Latest From Mirum Pharmaceuticals, Inc.

Orphans Dominate New US FDA Approvals, Thanks To Rethymic, Tavneos, And Livmarli

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Mirum Targets $500m Sales For Just-Approved Rare Liver Disorder Drug

Regulators have approved Mirum's IBAT inhibitor as the first medication for a genetic disorder which affects up to 2,500 children in the US.

Approvals Liver & Hepatic

Asia Deal Watch: Beximco Broadens Offerings, Capabilities With Sanofi Bangladesh Buy

Plus deals involving Biosplice/Haisco, SciClone/Tarveda, Everest/Sinovent/SinoMab, Kyowa Kirin/AM-Pharma, Sandoz/Bio-Thera, Dr. Reddy’s/Citius, Jiangsu Hengrui/Mabworks, GeneQuantum/BrightGene, Innovent/GenFleet and Takeda/Mirum.

Deal Watch Business Strategies

Korea Q2 Roundup: Mixed Bag As Pandemic Buoys Some, Hits Others

Two SK Group affiliates benefit from COVID-19 vaccine manufacturing activities and US sales of novel drugs, while other factors such as a recovery in prescription sales, new launches and falling milestone payments affected results at other traditional South Korean pharma firms in the second quarter.

South Korea Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register